The Deal Pipeline notes Fried Frank's representation of Merck in its acquisition of SmartCells

The Deal Pipeline notes Fried Frank's representation of Merck in its acquisition of SmartCells

The Deal Pipeline noted New York corporate partner David Shine's representation of Merck & Co., Inc. in its definitive agreement to acquire SmartCells, Inc., a private company developing a glucose-responsive insulin formulation which, if approved for use, could provide an important new therapy for the treatment of diabetes.

news-detail.inc